HighPoint Advisor Group’s Collegium Pharmaceutical COLL Stock Holding History

HighPoint Advisor Group’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,660	Closed	-$262K	–	730
2025 Q4	$262K	Sell	5,660 -1,050	-16%	-$43.9K	0.01%	910
2025 Q3	$235K	Buy	+6,710	New	+$233K	0.01%	610
2025 Q2	–	Sell	-7,790	Closed	-$215K	–	681
2025 Q1	$215K	Sell	7,790 -1,650	-17%	-$50.4K	0.01%	605
2024 Q4	$298K	Sell	9,440 -3,992	-30%	-$132K	0.02%	512
2024 Q3	$449K	Hold	13,432	–	–	0.03%	380
2024 Q2	$518K	Sell	13,432 -3,257	-20%	-$113K	0.03%	341
2024 Q1	$537K	Buy	16,689 +4	+0%	+$140	0.04%	333
2023 Q4	$670K	Buy	+16,685	New	+$418K	0.05%	287
2022 Q2	$422K	Buy	+21,906	New	+$369K	0.05%	318
2021 Q3	$594K	Sell	30,077 -550	-2%	-$11.9K	0.06%	276
2021 Q2	$724K	Buy	30,627 +118	+0.4%	+$2.73K	0.07%	230
2021 Q1	$712K	Sell	30,509 -7,806	-20%	-$185K	0.08%	200
2020 Q4	$997K	Buy	+38,315	New	+$748K	0.12%	144

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

HighPoint Advisor Group's COLL Position: Q1 2026 in Review

HighPoint Advisor Group sold out of Collegium Pharmaceutical (COLL) in Q1 2026, closing a stake of 5,660 shares — an estimated $262K sold.

HighPoint Advisor Group first reported a position in COLL in Q4 2020 and held it in 13 quarters. The position peaked at $997K in Q4 2020. 267 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

HighPoint Advisor Group reported no remaining Collegium Pharmaceutical position as of Q1 2026 after selling out during the quarter.
HighPoint Advisor Group sold 5,660 Collegium Pharmaceutical shares in Q1 2026, an estimated $262K.
HighPoint Advisor Group first reported a position in Collegium Pharmaceutical in Q4 2020 and held it in 13 quarters.
HighPoint Advisor Group's Collegium Pharmaceutical position peaked at $997K in Q4 2020.
267 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.